Top 5 Catalysts for Psychedelic Stocks In The Second Half of 2021 (MNMD,CMPS,ATAI,TRYP, CYBN & MORE)

Two Psychedelic Medicines Companies Run out of Money. What is next for psychedelic stocks? Plus a MindMed Stock Update( MMED / MMED)

Join our Newsletter (scroll to the bottom of the page and sign up): https://psychedelicspotlight.com/psychedelic-news/industry/

Follow us on Twitter:
@Psy_Invest
@psy_holy
@PsycSpotlight

Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight

To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/

Interested in going to Malta for Plant Medicine Week April 5th-8th? Get discounted tickets here: https://tickets.plantmedicineweek.com/attendance/event/index/41436/EN?promocodes=PSYC

A second domino is falling in the world of psychedelic stock investing.

Last week, Psychedelic Spotlight reported that Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) was halting its psychedelic medicines research, following a “strategic review” undertaken by the company.

In short, they ran out of money.

As I have stated repeatedly, running a psychedelic research company is ridiculously expensive, and many smaller companies with low market caps and little money in the bank will find it hard to survive in a market context of low stock prices.

At the time, I speculated that “we shouldn’t be surprised if this is just the first domino,” and unfortunately, it didn’t take much time for the prophecy to be realized.

On March 19th, psychedelics company Core One Labs (CSE: COOL) (OTC: CLABF) announced that they are “working to investigate investment and potential takeover opportunities by strategic psychedelics or pharmaceutical companies.”

Or, in other words, they too have run out of money and are looking for a financial savior.

This wasn’t particularly surprising. Taking a cursory look at their financials, we can see the dire position the company is in. As of the end of September, the company had $587,000 CAD in the bank, and they were spending more than $5 million per quarter. With a market cap of around $32 million, Core One would have to dilute their stock by more than 15% each quarter to keep spending at the same levels. This, obviously, is an unsustainable proposition.

So, with two psychedelic medicine companies essentially announcing that they no longer have the financial wherewithal to continue operations, does it mean that the end of psychedelic stocks is near?

No, it most certainly does not.

To start, we need to understand that the psychedelics companies that are beginning to falter are the ones who were already in bad financial shape. There are many companies that have strong financials, and do not need to worry about refinancing any time soon. A short and non-exhaustive list of these companies include: atai Life Sciences (Nasdaq: ATAI); MindMed (Nasdaq: MNMD) (NEO: MMED); and Small Pharma (TSXV: DMT) (OTCQB: DMTTF). Even if — and I judge this to be likely — more small-cap psychedelics companies follow Mind Cure and Core One Labs’ lead, the more financially stable companies won’t be affected.

Sources:

PsychedelicSpotlight.com article: https://psychedelicspotlight.com/another-psychedelics-company-core-one-labs-is-crashing-is-industry-in-trouble/

MindCure Press release: https://www.newswire.ca/news-releases/mindcure-provides-update-on-strategic-review-891232484.html

Core One Labs Press Release: https://www.globenewswire.com/news-release/2022/03/19/2406329/0/en/Core-One-Labs-to-Investigate-Soliciting-Investment-and-Potential-Takeover-Opportunities.html

Core One Labs $100/ gram psilocybin: https://www.globenewswire.com/news-release/2022/02/23/2390219/0/en/Vancouver-discovery-will-make-Magic-Mushroom-mental-health-care-cheaper.html

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#PsychedelicStocks #Psychedelics #Investing

Today we’ll discuss More MindMed Catalysts: MMED MMEDF Stock Opportunity (Plus Jr & Kevin O’Leary comments)

Today’s episode is a short follow up video to our last episode, where we looked at the catalysts for MindMed and MindMed stock in 2021.

We have already covered the NASDAQ uplisting, Clinical trial updates that MindMed will give this year and Conference calls and possible financing deals. But of course, we missed a few of important possible catalysts, as you guys so rightly pointed out.
So in this episode we are briefly going to run through them.

So what else can MindMed and MMED/MMEDF investors expect this year?

1. The imminent launch of the first Psychedelic Medicines ETF, The North American Psychedelics Index (PSYK)
-When will it launch?
-In what manner will it affect MindMed
-And how much it will influence MindMed’s stock price

2. Atai Life Sciences expected IPO how that’ll affect MindMed
– How will the IPO of another big rival will affect MMED/MMEDF?

3. Potential catalyst of Partnerships, Mergers and Acquisitions
-Coming directly from an Interview with JR Rahn and Kevin O’Leary

Unlike the 1st two catalysts we discuss here, as well as a potential Nasdaq uplisting, future partnerships mergers and acquisitions would affect MindMed’s long term value, and their ability to develop, produce and distribute game changing medicines.

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com

https://mindmed.co/news/press-release/mindmed-expands-psychedelic-microdosing-division-adds-groundbreaking-study-evaluating-lsd-microdosing-through-next-gen-digital-clinical-markers/

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

#MindMed #MMED #MMEDF

Hello back Psychedelic Investors! In this video we are going to be entering the Speculation Zone to discuss the implications of several of MindMed’s most recent moves. Aka, we shall be Speculating on The Future of MindMed [Big News for MMED/MMEDF STOCK].

Timestamps:
0:00 – Intro
2:52 – Speculating on LSD Trials
7:44 – MindMed’s Partnership Meaning
13:45 – Nasdaq Uplisting

This is actually the second video being released today. Earlier we posted a video detailing the three most recent press releases distributed by MindMed, where we explained what each move meant. If you haven’t seen that episode yet and want to get a detailed explanation of each Press Release before watching this video speculating on that information, you should probably do that first!

Well actually, MindMed has since released another press release since the first video was filmed, on the commencement of their LSD Neutraliser phase 1 clinical trial.
In our Video on MindMed’s Latest News, we discussed:

1. How MindMed has started a phase 1 clinical trial studying the effects of mixing LSD and MDMA;
2. We examined MindMed’s changes in Leadership, where JR Rahn became the sole CEO, and a gentleman by the name of Dr. Glick left the board;
3. We also talked about MindMed’s new partnership with a company called MindShift Compounds AG, which is developing novel compounds owned exclusively by MMED.

In this video, we discuss/SPECULATE on all of MindMed’s latest changes and how some of them could potentially influence the MMED/MMEDF stock’s uplisting on NASDAQ.

I hope you guys found some value in this and I’ll keep you posted for more changes!

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
Video by Pressmaster from Pexels

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

#MindMed #MMEDF #MindmedStock